Header Logo

Connection

Usman Baber to Aortic Valve Stenosis

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Aortic Valve Stenosis.
Usman Baber
Connection Strength
4.104
Aortic Valve Stenosis
  1. Impact of Frailty on Outcomes in Patients Who Underwent Transcatheter Mitral Valve Replacement. Am J Cardiol. 2023 09 15; 203:301-303.
    View in: PubMed
    Score: 0.812
  2. Aortic stenosis: role of balloon aortic valvuloplasty. Cardiol Clin. 2013 Aug; 31(3):327-36.
    View in: PubMed
    Score: 0.406
  3. Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). Am J Cardiol. 2022 06 01; 172:73-80.
    View in: PubMed
    Score: 0.186
  4. Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheter Cardiovasc Interv. 2021 11 15; 98(6):E908-E917.
    View in: PubMed
    Score: 0.175
  5. Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. Catheter Cardiovasc Interv. 2021 04 01; 97(5):E704-E715.
    View in: PubMed
    Score: 0.167
  6. Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. Int J Cardiol. 2021 01 01; 322:65-69.
    View in: PubMed
    Score: 0.165
  7. The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. Catheter Cardiovasc Interv. 2020 07; 96(1):198-207.
    View in: PubMed
    Score: 0.159
  8. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheter Cardiovasc Interv. 2020 12; 96(7):E688-E694.
    View in: PubMed
    Score: 0.159
  9. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 01 15; 125(2):251-257.
    View in: PubMed
    Score: 0.157
  10. Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Can J Cardiol. 2019 02; 35(2):199-207.
    View in: PubMed
    Score: 0.147
  11. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.147
  12. Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). Am J Cardiol. 2018 12 01; 122(11):1909-1916.
    View in: PubMed
    Score: 0.145
  13. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018 11; 205:63-69.
    View in: PubMed
    Score: 0.144
  14. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. JACC Cardiovasc Interv. 2018 01 08; 11(1):1-12.
    View in: PubMed
    Score: 0.138
  15. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
    View in: PubMed
    Score: 0.134
  16. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1027-1037.
    View in: PubMed
    Score: 0.133
  17. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. 2016 Dec 27; 68(25):2733-2744.
    View in: PubMed
    Score: 0.129
  18. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
    View in: PubMed
    Score: 0.127
  19. Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 10 24; 9(20):2124-2133.
    View in: PubMed
    Score: 0.127
  20. Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. Am Heart J. 2015 Jul; 170(1):180-6.
    View in: PubMed
    Score: 0.114
  21. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention. 2014 Jul; 10(3):312-9.
    View in: PubMed
    Score: 0.108
  22. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis. 2013 May; 35(4):483-93.
    View in: PubMed
    Score: 0.100
  23. The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv. 2014 Jan 01; 83(1):148-53.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.